
Part One: The Question of MRD in CLL Therapy
The HemOnc Pulse
Comparative Analysis of BTK Inhibitors for CLL Therapy and Treatment Options
This chapter analyzes the differences between acalabrutinib and zanabrutenev as BTK inhibitors for CLL treatment, considering factors like efficacy, dose reduction, and switching options in light of evolving treatment choices.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.